Inactive Instrument

Other languages Mologen AG Deutsche Boerse AG

Equities

DE0006637200

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Mologen AG Announces Updates on Phase III IMPALA Study; Provides Earnings Guidance for the Full Year 2019	14/19/14
Mologen AG Announces Management Changes	27/19/27
Mologen AG Announces Management Changes	01/18/01
Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018	20/18/20
Mologen Reports Earnings Results for the Six Months of 2016; Provides Earnings Guidance for the Full Year of 2016	17/16/17
Mologen AG Announces Progress in Clinical Studies; Announces Earnings Results for the First Quarter of 2016; Confirms Earnings Guidance for the Year 2016	12/16/12
Mologen AG Reports Earnings Results for the Year 2015	22/16/22
MOLOGEN AG Appoints Walter Miller as Member of the Executive Board and Chief Financial Officer with Effect from April 1, 2016	16/16/16
Mologen AG Announces Extension of TEACH Study Based on Supportive First Study Results	14/16/14
Mologen AG Supports Development Strategy of lefitolimod (MGN1703)	25/16/25
MOLOGEN AG and the University of Texas MD Anderson Cancer Center Enter into Collaboration Agreement Relating to Phase I trial with MOLOGEN’s Immunomodulator Lefitolimod in Combination with the Immunotherapy Yervoy® in Patients with Advanced Solid Malignancies	19/16/19
MOLOGEN AG Reaffirms Earnings Guidance Financial Year 2015	12/15/12
Mologen AG(XTRA:MGN) dropped from S&P Global BMI Index	21/15/21
Mologen AG Reports Earnings Results for the First Half of 2015	13/15/13
MOLOGEN AG Announces Managements Changes	23/15/23
Mologen Holding AG’s Equity Buyback announced on June 7, 2010 has expired.	07/15/07
Aarhus University Hospital Initiates MGN1703 Study in HIV Patients	09/15/09
MOLOGEN AG Presents Data Supporting Administration Scheme of MGN1703 at ITOC-2 Conference 2015	30/15/30
Mologen Reports Earnings Results for the Year 2014	25/15/25
Mologen AG Presents Subgroup Analysis from Impact Study and Design of Pivotal Impala Trial	19/15/19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mologen AG Deutsche Boerse AG

Equities

DE0006637200

Other languages

Filters